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ABSTRACT 
 
The purpose of the present thesis was to propose a guideline to 
differentiate between an accidental or suicide manner of death when dealing with 
a drug/ethanol overdose in which all available medical and investigational 
evidence, including a psychological autopsy, is inconclusive, thereby resulting in 
an undetermined manner of death. An in-depth literature review was conducted 
in the field of neuroscience, psychiatry, and pharmacology to discover 
neuroanatomical markers indicative of suicidal behavior in the context of two 
major risk factors of suicide, stress and depression, and two hypotheses behind 
the cause of suicidal behavior, impulsive aggression and neuronal plasticity. The 
neuroanatomical markers of suicidal behavior, as indicated by the experimental 
evidence of various studies in suicide subjects, included serotonergic 
dysfunction, hypothalamic-pituitary-adrenal axis hyperactivity, brain-derived 
neurotrophic factor deficiency, and the associated anatomical changes in the 
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brain. Upon consideration of the forensic applicability of analyzing these 
neuroanatomical markers indicative of suicidal behavior, a guideline was 
generated to differentiate between an accidental and suicide manner of death by 
showing suicide subjects had significantly decreased messenger ribonucleic acid 
and protein levels of presynaptic serotonin receptors along with significantly 
increased messenger ribonucleic acid and protein levels of postsynaptic 
serotonin receptors in the prefrontal cortex, significantly decreased serum brain-
derived neurotrophic factor levels, and significantly decreased messenger 
ribonucleic acid and protein levels of brain-derived neurotrophic factor and 
tyrosine kinase B receptors in the prefrontal cortex and hippocampus when 
compared to the levels of both depressed non-suicidal individuals and healthy 
controls. Given the significant difference observed between suicide subjects and 
controls, these differences in neuroanatomical markers may play an important 
role in the pathophysiology of suicidal behavior and have the potential to be used 
in establishing the intention of an individual in an overdose death to distinguish 
between an accidental or suicidal manner of death. 
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1. INTRODUCTION 
 
Death is one of the inevitable events that have always been a target for 
explanation and understanding. Theorized by intellectuals, researched by 
scientists, and respected by the religious, death has been interpreted in a variety 
of ways throughout the ages by personal, scientific, and religious beliefs. For 
medical examiners, it is their duty and profession to understand the physical 
mechanics behind an individual’s death and explain why the fatal event occurred 
through the combination of an autopsy, history review, and death scene 
investigation. Although medical examiners may not always personally conduct 
the death scene investigation or interview the next of kin for the deceased’s 
social, medical, and psychiatric history, which are tasks typically left to 
medicolegal investigators, medical examiners are solely responsible for 
performing the medico-legal autopsy.  
 The medico-legal autopsy generally begins with the external examination 
of the body. After the collection of trace evidence, removal of clothing, clean-up, 
and photographic documentation, the physical features of the body are recorded 
and examined for the presence of wounds. The autopsy proceeds with the 
internal examination of the body where viscera, cavities, and bones are 
inspected for trauma, deformity, or lesions. Additional toxicological and 
histological examination may also be performed but at the discretion of the 
medical examiner [1]. Regardless of any possible variations in the steps taken, 
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the reason behind the autopsies remains the same; to determine the cause and 
manner of death.  
 The cause of death is a general term used to describe the lethal series of 
events that led up to an individual’s demise. In typical medico-legal practice, the 
cause of death describes how an individual died and is differentiated into two 
separate identities: the proximate cause of death and the immediate cause of 
death [2]. The proximate cause of death refers to the original injury or disease 
that is responsible for initiating the lethal chain reaction. There can only be one 
injury or disease responsible for the proximate cause of death. In contrast, the 
immediate cause of death refers to the medical complications resulting from the 
proximate cause of death. For example, if an individual was stabbed in a way 
that was not directly lethal but develops into a fatal case of sepsis and peritonitis 
days later, the proximate cause of death would be the stab wound and the 
immediate causes of death would be both sepsis and peritonitis. Compared to 
the immediate cause of death, the proximate cause of death can be more 
challenging to establish, especially if separated by an extended period of time, 
but can be used in the determination of the manner of death.    
 The manner of death refers to a classification scheme used to differentiate 
why an individual died. In contrast to the cause of death, which is strongly 
supported by empirical medical data from autopsies, the manner of death relies 
more on the combination of death scene findings and third party information such 
as witness testimonials, police reports, and family interviews. Although there are 
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no globally accepted standards to how a manner of death is classified [8], five 
broad categories are recognized to describe the circumstances behind a death: 
natural, accident, suicide, homicide, and undetermined. 
 A natural manner of death generally encompasses the deaths caused 
solely by disease. The term disease may include adverse effects due to chronic 
abuse to the body from factors such the environment, drugs, genetics, and aging. 
As a result of the broad definition, the leading majority of deaths annually are 
comprised of natural deaths. Sometimes, the assignment of a natural manner of 
death may be complicated, due to sharing similar scenarios as accidental deaths, 
but are usually differentiated by a measure of time between symptoms and the 
fatal event. For example, in a fatal case of acute alcohol intoxication, a chronic 
alcoholic would be assigned a natural manner of death while a teenager who 
experimented with alcohol for the first time would be assigned an accidental 
manner of death [2]. The only difference between the two scenarios is that the 
chronic alcoholic already had adverse medical symptoms, such as liver cirrhosis, 
developed over a period of time from alcoholism and exacerbated to the point of 
being lethal, while the teenager did not. 
 A report of accidental manner of death is less prevalent than natural 
manner of death and includes all deaths caused by a fatal injury that was not 
expected or intended. However, the specific requirement for a death to be 
classified as an accident is proof that the death was not caused intentionally, 
either by the deceased or by another person [2]. The majority of accidental 
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manner of deaths can be contributed to impairment, ignorance, or human error 
with the two leading causes of death, as categorized by the Centers for Disease 
Control and Prevention mortality database, being motor vehicle traffic and drug 
intoxications. 
 A suicide manner of death is more refined in definition and includes all 
deaths where the decedent was held accountable for the fatal injury. In contrast 
to accidental manner of death, in order to be classified as a suicide, the fatal 
injury must be self-inflicted and shown to have been performed intentionally [2]. A 
reasonable amount of medical certainty must accompany the determination 
otherwise, due to the difficult nature of suicide and the stigma it bears, the 
classification of suicide will sometimes be controversial and amended. Therefore, 
the determination of a suicide manner of death is usually preceded by a 
psychological autopsy. In a psychological autopsy, medical examiners consider 
the social and medical details of the deceased’s life for factors that have been 
shown to be linked to suicide epidemiology. Social details encompass anything 
within the individual’s social context such as personal difficulties, working 
conditions, and the level of social interaction. Medical details encompass 
anything related to the individual’s physical and mental history such as physical 
ailments, mental disorders, accounts of intentional self-harm, and communication 
records between health professionals or help line services. The purpose behind 
the collection of social and medical details is to gather explicit and/or implicit 
evidence of the decedent’s intention or desire to kill one self while being 
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cognizant of the consequences of their actions. The evidence gathered from 
suicide investigations are typically used to answer the questions if there were the 
presence of stressful events or mental disorders, previous experiences with 
suicide, efforts undertaken by the decedent to prevent rescue, and the 
inappropriate preparation and expression of farewell and impending death in the 
context of the decedent’s life. The amount of evidence sufficient enough to 
determine a suicide manner of death is ultimately up to the discretion of the 
medical examiner [4]  
 An undetermined manner of death includes deaths which could not be 
classified under the four other manners of death. The determination of 
undetermined is used when a death cannot be differentiated between any of the 
other four manners of death with more than 50% certainty, despite consideration 
of all available evidence [3]. The classification of undetermined is mainly used 
when information is insufficient or when the cause of death cannot be determined 
due to uninformative circumstances such as skeletonized remains. As a result, 
undetermined manner of death may leave issues unresolved.      
Given the professional responsibility of medical examiners and the social, 
financial, legal, and religious influence a determination of death may have on the 
lives of the decedent’s next of kin, it is important, from a moral and ethical 
perspective, that medical examiners base their findings on all the available facts 
known and their diagnosis is accurate and indisputable, regardless of the 
consequences. However, the information collected to help establish the cause 
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and manner of death may not always be useful. As mentioned earlier, during a 
psychological autopsy, the deceased’s social, medical, and psychiatric histories 
are collected from next of kin, alongside witness testimonials, and taken into 
consideration when assigning the manner of death. For some families, the 
outcome of the diagnosis may affect them negatively for social, financial, 
religious, or legal reasons, especially with suicide determinations, therefore 
cooperation during interviews and investigations may not always be expected. As 
a result, medical examiners may end up with unsubstantiated or even false 
information. Therefore, until new empirical methods of collecting evidence are 
discovered, medical examiners may continue to have difficulty in assigning a 
manner of death, other than undetermined, in cases that can be diagnosed by 
more than one manner of death based on circumstantial evidence. Although the 
assignment of undetermined manner of death is the appropriate result when 
there is insufficient evidence, the current knowledge of differentiating between 
manners of death can be expanded and improved upon.  
The thesis will focus on a very specific example of this scenario, in 
particular drug/ethanol overdoses, in which all available information is 
insufficient, even after a psychological autopsy, to distinguish between a suicide 
and accidental manner of death, therefore labeled as an undetermined manner of 
death. The occurrence of the proposed scenario of drug/ethanol overdose in 
conjunction with insufficient evidence may seem limited in scope, a review of the 
underlying causes of death in the U.S. would suggest otherwise. Over the time 
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period of 1999-2009, the number of undetermined deaths reported annually in 
the United States had risen at a steady pace with overdose by drugs and ethanol 
consistently comprising the majority of the causes of death. Since overdose 
fatalities by homicide are generally rare and standard toxicological screening, 
autopsy, or testimony from next of kin can usually exclude a natural manner of 
death, it would be justifiable to assume the majority of overdose fatalities by 
drugs and ethanol were assigned an undetermined manner of death because of 
the difficulty in differentiating between a suicide or accidental manner of death. 
This assumption has been supported by several studies which have 
demonstrated an underreporting of suicide and accident as manners of death in 
overdose deaths while an increase in the assignment of undetermined. In one 
particular study of undetermined overdose deaths in Utah, the authors abstracted 
all suicides and one half of all accidental and undetermined overdose deaths for 
data and using bivariate analyses of the differences in contributing factors 
between suicides and accidental overdose deaths such as a history of 
depression and suicidal behavior, a classification tree was created to reclassify 
undetermined overdose deaths. Using this approach, the authors demonstrated 
that up to 30% of suicides and approximately 61% of accidental deaths were 
underreported [6, 7, 15-19].  
The differentiation between a suicide and accidental manner of death is 
typically determined by establishing the intention of the decedent prior to death. 
Ante-mortem toxicology levels of most drugs and ethanol are estimated in 
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correlation to measured post-mortem levels which may be subjected to the 
effects of various post-mortem processes [8-11]. For example, ethanol, which is 
one of the most abused drugs in the world, may have post-mortem levels that are 
increased due to microbial fermentation or levels that are decreased due to 
redistribution [12]. Despite variations in post-mortem levels, medical examiners 
usually know how to interpret post-mortem drug and ethanol levels and assign a 
manner of death. However, in conjunction with toxicological testing, as 
mentioned earlier when defining the manners of death, intention at a legally 
defined level must also be shown before a death can be labeled as suicide. This 
proves especially difficult when direct indications of intent are unavailable; 
suicides are usually solitary acts with no witnesses and suicide notes are only 
found in approximately 1 out of every 3 suicides [13, 14].  
Without explicit or circumstantial evidence of intention, medical examiners 
may be unable to decide if there is enough compelling information, even after a 
psychological autopsy, to classify a fatality by drug/ethanol overdose as an 
accident or suicide; currently, no recognized method exists to differentiate 
between these two manners of death in this scenario. The thesis will attempt to 
resolve this difficulty in classification by assessing the biological mechanisms 
mediating suicidal behavior and highlighting the anatomical differences observed 
between suicidal and non-suicidal behavior to discriminate between suicide and 
accidental manner of death.  
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2. AIM AND OBJECTIVES 
 
The aim of this study was to suggest methods which may be able to 
increase the accuracy of a medical examiner’s diagnosis with the goal of 
developing a new approach to the determination process for manner of death in 
drug/ethanol overdoses where information is insufficient despite complete 
medical and scene investigation. Three objectives were considered in order to 
accomplish this goal. The first objective was to identify potential hypotheses to 
explain the pathophysiology of suicide. The second objective was to present 
support for these hypotheses through direct and indirect evidence obtained from 
a thorough literature review. The direct evidence consisted of induced anatomical 
and neurochemical changes of the brain derived from controlled animal or human 
studies that simulated predisposing factors of suicidal behavior. The indirect 
evidence, on the other hand, consisted of circumstantial patterns of differences 
between suicide subjects and controls from in vivo and post-mortem studies. The 
third and final objective was to compare these findings and incorporate the 
validity and forensic applicability of each hypothesis into a method of analysis 
that could be further researched by the medical community for potential practice. 
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3. METHODS 
 
3.1. Evaluation of Evidence 
To approach the process of formulating a test to prove intention, a 
literature review was performed to establish a commonality between cases of 
suicides. The most common association observed from publications was a 
prevalence of mental illness. Several studies showed a consistently high 
proportion of suicides, ranging from 68 to 100 percent, were diagnosed with one 
or more forms of mental illness before the suicide was committed [17, 20, 21, 22, 
23]. Since mental illness can be linked to defects in anatomy, it was conjectured 
that a possible connection could exist between defects in the anatomy of the 
brain and the intention to commit suicide. Clinical brain function studies were 
evaluated for potential anatomical differences that can be observed in 
postmortem scenarios. In addition, past studies have shown a connection 
between chemical levels in the brain and linked behavior; for example, 
testosterone, which is a chemical molecule that has its corresponding receptor 
located in the brain, has been shown to increase aggressive behaviors [24]. 
Thus, with this example of chemically-mediated behavior in mind, an in-depth 
literature search was undertaken in established journals within the field of 
neuroscience, psychiatry, and pharmacology to find potential chemical signaling 
molecules that may serve as a pathological marker for suicide. In order for a 
case study to be considered as a supporting item of evidence, the article must 
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have demonstrated a level of evidence of 3 or lower. Research with level 1 
evidence consisted of randomized controlled trials, research with level 2 
evidence consisted of non-randomized controlled trials, and research with level 3 
evidence consisted of observational studies with controls. Any article that did not 
satisfy this requirement was excluded from this study. 
 
4. RESULTS / LITERATURE REVIEW 
 
 Upon performing the initial literature review, two popular hypotheses were 
adopted as potential candidates to explain the pathophysiology of suicide. The 
first hypothesis was characterized by abnormal levels of monoaminergic 
neurotransmitters and proposed that suicide was the result of the adverse 
combination between an impulsive-aggressive personality and chronic 
stress/depression. In comparison, the second hypothesis was characterized by 
the reduced expression of neurotrophic factor, in particular, brain-derived 
neurotrophic factor (BDNF), and proposed that suicide occurs when the affected 
individual’s brain could no longer adaptively respond to stimuli due to a state of 
reduced neuronal plasticity. Neuronal plasticity refers to the capacity of the brain 
to change in response to stimuli through the generation and reorganization of 
neurons. The following review will discuss the supporting literature that 
demonstrated direct and indirect evidence of the validity and forensic applicability 
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of each hypothesis in the context of two major risk factors associated with 
suicide: stress and depression.  
 
4.1. Suicide Risk Factors 
 
Stress 
 In a biological sense, stress can be defined as the body’s physiological 
and psychological response to a stressor, typically an environmental change or 
stimuli. The responses are generally mediated by a variety of hormones but two 
classes of hormones have been recognized as the major contributors. The first 
class of hormones are the catecholamines with emphasis being placed on 
epinephrine and norepinephrine. Epinephrine and norepinephrine are two 
different neurotransmitters that are immediately released from storage in the 
adrenal medulla and locus ceruleus, respectively, upon the detection of a 
stressor and are responsible for initiating the series of biochemical changes 
associated with the fight or flight response.  
The second class of hormones is the glucocorticoids which consist of 
cortisol and corticosterone. After the initial detection of stress, glucocorticoids are 
released from the adrenal cortex following a hormonal cascade through the 
hypothalamic-pituitary-adrenal (HPA) axis. In the HPA axis, corticotrophin-
releasing factor (CRF) is released from the hypothalamus, resulting in the 
increase of adrenocorticotropin hormone (ACTH) secretion from the anterior 
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pituitary, which consecutively induces the release of glucocorticoids from the 
adrenal cortex [25]. The released glucocorticoids migrate to target tissues 
throughout the peripheral circulation, bind to intracellular receptors to enter cell 
nuclei, and either promote or inhibit gene transcription. Compared to the 
immediate effects of catecholamines, the resulting physiological effects of 
glucocorticoids are broader, delayed, and more persistent (Figure 1). 
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Figure 1. Hormonal response to stress by the adrenal cortex and medulla. 
Catecholamines (norepinephrine and epinephrine) are released from storage in 
the adrenal medulla and glucocorticoids are released from the adrenal cortex. 
Glucocorticoid release is controlled by negative feedback inhibition. 
 
When faced with acute challenges of stress, the extracellular 
concentration of catecholamines and glucocorticoids become elevated and their 
combined physiologic effects may help promote the survival of the individual. 
Upon the termination of the acute stress response, these elevated hormone 
levels are typically returned to baseline values by their respective system of 
feedback inhibition [26]. Chronic stress, on the other hand, may exacerbate the 
physiological changes mediated by catecholamines and glucocorticoids. 
Normally, under stress free conditions or upon the termination of acute stress, a 
rise in glucocorticoids stimulates the receptors on the hippocampus, which inhibit 
CRF release from the hypothalamus through the mechanism of negative 
feedback, thereby preventing subsequent CRF-stimulated ACTH secretion from 
the anterior pituitary and ACTH-stimulated glucocorticoid secretion from the 
adrenal cortex [27, 28]. During chronic stress, on the other hand, the HPA axis 
becomes hyperactive due to a dysregulation in the negative feedback system of 
the hippocampus. This dysregulation can be attributed to the combination of the 
body’s increased energy demands during an extended stress response, the 
catabolic, or energy producing, nature of glucocorticoids, and the fight of flight 
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response. A large quantity of glucose is constantly metabolized as an energy 
source by the large muscles of the body under stressful conditions and 
glucocorticoids carry out the essential role of inducing changes to meet the 
metabolic demand by promoting gluconeogenesis.  The fight or flight response, 
on the other hand, inhibits the uptake of glucose in tissues that are not 
immediately required for survival. When combined together, these glucocorticoid-
induced changes elevate the concentration of circulating glucose available for 
immediate use in the muscles, heart, and brain.  
However, this system of energy production may become deleterious as 
glucose is continuously shunted from vulnerable tissues such as the brain. Since 
glucose is the only energy source for brain tissue, the depletion of glucose may 
lead to impaired functionality or even neural degeneration. Several studies have 
shown that prolonged stress can inhibit glucose transport and metabolism in the 
hippocampus, which in turn will eventually lead to the downregulation of 
glucocorticoid receptors in the hippocampus that facilitate the negative feedback 
response of the HPA axis [29-37]. With this glucocorticoid-induced impairment of 
the hippocampus, the HPA axis will continue to secrete for the duration of the 
stress response despite abnormally high levels of circulating glucocorticoids. 
Although an elevated level of glucocorticoids may enhance survival during acute 
challenges of stress by mobilizing glucose, a prolonged exposure to 
glucocorticoids may elicit the degeneration of areas in the brain responsible for 
averting suicidal behavior. 
16 
 
Depression 
 Depression can generally be defined as a mental state of altered mood 
characterized by anhedonia, anxiety, fatigue, and self-directed animosity. 
Depression poses a significant risk factor for suicidal behavior and exhibits 
physiological adaptations similar to those seen during a chronic stress response. 
It has been proposed that depression is a byproduct of chronic stress and the 
similarity in adaptive responses can be attributed to the use of the same effectors 
in the HPA axis and locus ceruleus, even though the means in which the 
changes are induced have been indicated to be different [38]. For example, 
during stress situations, circulating glucocorticoids bind to receptors on the locus 
ceruleus and increase the activity of tyrosine hydroxylase, an enzyme 
responsible for the biosynthesis of catecholamines [39]. In acute challenges of 
stress, this increase in tyrosine hydroxylase activity elevates catecholamine 
secretion to promote survival; however, in chronic stress, the constant increased 
activity of tyrosine hydroxylase eventually leads to the depletion of available 
norepinephrine [40]. In depression, on the other hand, a similar deficiency in 
norepinephrine secretion is observed and is postulated to be connected to 
biochemical lesions of the norepinephrine system. These abnormalities, whether 
genetic, stress-induced, or a combination of both, are broad and include 
possibilities such as fewer noradrenergic neurons in the locus ceruleus, altered α 
and β adrenergic cortical receptor binding, and inadequate stimulation of tyrosine 
hydroxylase activity by glucocorticoids [38, 41-44].   
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4.2. Hypotheses of Suicide Pathophysiology 
 
Impulsive Aggression and Suicidal Behavior 
The connection between suicidal behavior and personality traits has 
become an increasingly researched subject over the past few decades. 
Personality traits, which are molded throughout childhood and stabilized during 
adulthood, provide a glimpse into how an individual perceives, adapts, and reacts 
to their environment [45, 46]. Since the act of suicide is reflective of the inability 
to cope with life situations, such as stress and depression, the difficulty for some 
individuals to adapt suggests that certain personality traits are predisposed to 
suicidal behavior. A review of clinical and population research has shown 
impulsive and aggressive personality traits in suicidal behavior [47-59]. Impulsive 
and aggressive personality traits, which were characterized by aggressive 
behavior, impulsivity, and Cluster B borderline personality disorder, were 
observed in a significant proportion, ranging from 25% to 60%, of subjects with 
suicide ideation, attempts, and completions (Table 1).  
 
Table 1. Impulsivity and Aggression in Suicide Ideation, Attempters, and 
Completers According to Individual Studies. 
Author Total Subjects / Controls Suicide Ideation Suicide Attempters Suicide Completers 
18 
 
Sarchiapone 
M, et al. 
903 male 
prisoners 
395 (31.9% of 
which showed 
aggressive 
behavior) 
131 (42% of which 
showed aggressive 
behavior) 
N/A 
Dumais A, et 
al. 
178 depressed 
males N/A N/A 
104 (41.5% of 
which showed 
aggressive 
impulsive 
behavior) 
Mann JJ, et al. 347 psychiatric patients N/A 
107 (60% of which 
showed impulsive 
aggressive 
behavior) 
N/A 
Carli V, et al. 1265 male prisoners 
536 (28.5% of 
which showed 
high impulsivity) 
164 (26.8% of 
which showed high 
impulsivity) 
N/A 
Oquendo MA, 
et al. 
308 mood 
disorder 
patients 
N/A 
159 (56.6% of 
which showed 
impulsive 
aggressive 
behavior) 
N/A 
Beautrais AL, 
et al. 
128 suicide 
attempters / 
153 control 
subjects 
N/A 
128 (39.8% of 
which showed high 
impulsivity) 
N/A 
Zouk H, et al. 164 subjects N/A N/A 
100 (25% of which 
showed aggressive 
impulsive 
behavior) 
 
In addition, the subjects with suicide ideation, attempts, and completions, 
when compared to controls, generally had a higher score for aggression and 
impulsivity when measured by the Brown-Goodwin Assessment for Lifetime 
History of Aggression (BGLHA), Barratt Impulsiveness Scale (BIS), and the 
Buss-Durkee Hostility Inventory (Table 2).The consistent difference in the level of 
aggression and impulsivity observed in Table 2 between suicide ideators, 
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attempters, completers, and controls provide support for a connection between 
suicidal behavior and personality traits. Furthermore, twin studies have shown 
the heritability of impulsive aggression through the studies of 800 monozygotic 
and dizygotic twin pairs raised together or apart, thereby suggesting the 
possibility of a genetic component for the susceptibility of suicidal behavior in 
individuals with impulsive-aggressive traits [60, 61]. Since genes are responsible 
for the particular phenotype of an individual and impulsive aggression has been 
associated with a high proportion of suicidal behavior, the observation of 
distinctive neuroanatomical abnormalities in individuals with impulsive-aggressive 
traits may help explain the pathophysiology of suicide.  
 
Table 2. Mean Aggression and Impulsivity Scores in Suicide Ideation, 
Attempters, Completers, and Controls According to Individual Studies. BGLHA = 
Brown-Goodwin Assessment for Lifetime History of Aggression. BIS = Barratt 
Impulsiveness Scale. 
Author 
Total 
Subjects / 
Controls 
Suicide 
Attempters / 
Completers 
Never 
Attempted / 
Controls 
Suicide 
Ideation 
No Suicidal 
Ideation 
Sarchiapone 
M, et al. 
903 male 
prisoners 
N= 131; BGLHA 
Aggression 
Score: 41.47 ± 
11.85 
N= 772; BGLHA 
Aggression 
Score: 34.71 ± 
10.46 
N= 395; 
BGLHA 
Aggression 
Score: 39.57 
± 11.13 
N= 508; BGLHA 
Aggression 
Score: 32.65 ± 
9.74 
N= 131; BIS 
Impulsivity 
Score: 48.50 ± 
16.25 
N= 772; BIS 
Impulsivity 
Score: 46.93 ± 
14.74 
N= 395; BIS 
Impulsivity 
Score: 48.44 
± 15.34 
N= 508; BIS 
Impulsivity 
Score: 46.14 ± 
14.61 
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Dumais B, et 
al. 
104 suicide 
completers 
/ 74 
controls 
N= 69; BIS 
Impulsivity 
Score: 67.37 
N= 69; BIS 
Impulsivity 
Score: 64.34 
N/A N/A 
N= 55; BGLHA 
Aggression 
Score: 13.75 
N= 62; BGLHA 
Aggression 
Score: 8.09 
N/A N/A 
McGirr A, et 
al. 
645 suicide 
completers 
/ 246 
controls 
N= 176; BIS 
Impulsivity 
Score: 66.52 ± 
14.83 
N= 176; BIS 
Impulsivity 
Score: 67.46 ± 
13.63 
N/A N/A 
N= 176; BGLHA 
Aggression 
Score: 9.99 ± 
12.34 
N= 176; BGLHA 
Aggression 
Score: 9.85 ± 
11.39 
N/A N/A 
Mann JJ, et 
al. 
347 
psychiatric 
patients 
N= 106; BIS 
Impulsivity 
Score: 54.0 ± 
16.1 
N= 97; BIS 
Impulsivity 
Score: 44.8 ± 
15.0 
N/A N/A 
N= 151; BGLHA 
Aggression 
Score: 22.0 ± 
6.6 
N= 131; BGLHA 
Aggression 
Score: 17.4 ± 
5.5 
N/A N/A 
Carli V, et al. 1265 male prisoners 
N= 106; BIS 
Impulsivity 
Score: 54.0 ± 
16.1 
N= 97; BIS 
Impulsivity 
Score: 44.8 ± 
15.0 
N/A N/A 
N= 151; BGLHA 
Aggression 
Score: 22.0 ± 
6.6 
N= 131; BGLHA 
Aggression 
Score: 17.4 ± 
5.5 
N/A N/A 
Oquendo 
MA, et al. 
308 
depressed 
patients 
N= 113; BIS 
Impulsivity 
Score: 54.7 ± 
17.0 
N= 107; BIS 
Impulsivity 
Score: 46.2 ± 
17.7 
N/A N/A 
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N= 138; BGLHA 
Aggression 
Score: 19.9 ± 
6.0 
N= 120; BGLHA 
Aggression 
Score: 16.8 ± 
4.7 
N/A N/A 
Michaelis 
BH, et al. 
52 bipolar 
patients 
N= 27; BIS 
Impulsivity 
Score: 70.1 ± 
11.9 
N= 25; BIS 
Impulsivity 
Score: 64.2 ± 
10.1 
N/A N/A 
N= 27; Buss-
Durkee 
Hostility Mean: 
42.4 ± 13.1 
N= 25; Buss-
Durkee 
Hostility Mean: 
27.5 ± 11.9 
N/A N/A 
 
Impulsive-aggressive behavior, which is characterized by hostile or 
injurious behavior in response to provocation, has a well-supported history of 
being associated with characteristic abnormalities of the frontal lobe, a region of 
the brain linked to the suppression of emotion [62]. The impaired function of the 
frontal lobe, due to injury, has been shown to be responsible for modulating 
impulsive-aggressive behavior and was first recognized in the famous case of 
Phineas Gage. Initially described as a responsible and socially well-adjusted 
individual, after surviving a considerable injury in which a tamping rod pierced 
through his orbital frontal cortex, Phineas Gage became irritable, capricious, and 
verbally abusive [63-65]. Comparable behavior was observed in returning 
soldiers of the Vietnam War who suffered penetrating head injuries in the same 
area [66]. Besides physical injuries, metabolic deficiency of the frontal lobe has 
also been indicated in impulsive-aggressive behavior. Brain imaging studies of 
the frontal lobe in violent murderers, psychiatric patients of borderline personality 
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disorder, and individuals with a history of aggression has exhibited decreased 
levels of glucose metabolism in comparison to controls [67-70]. For example, a 
study of local cerebral uptake in glucose using positron emission tomography in 
22 murderers and 22 age/gender-matched controls showed lower glucose 
metabolism in both lateral and medial portions of the prefrontal cortex (Figure 2).  
 
 
Figure 2. Relative glucose metabolic values for overall left and right medial 
prefrontal cortex and for overall left and right hemisphere lateral prefrontal cortex 
in murderer and controls. Data adapted from Raine A et al., 1994. 
 
This deficiency in glucose metabolism can be attributed to an observed 
reduction in regional cerebral blood flow during an aggressive response. In an 
imaging study, healthy volunteers, with no history of abnormal behavior, 
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displayed lower levels of blood flow to the orbital frontal cortex during imagery 
scenarios that elicited aggressive behavior [71]. Moreover, individuals associated 
with impulsive-aggressive behavior such as murderers, alcoholics with antisocial 
personality disorder, and patients with personality disorders showed 
hypoperfusion of the prefrontal cortex when compared to controls [70, 75, 76]. 
The reduction in blood flow and glucose metabolism together suggests a 
functional deactivation of the frontal lobe in impulsive-aggressive personalities 
and is similar to the significant reduction of local cerebral glucose utilization seen 
in animal studies of GABA receptor agonist-induced inhibition of cortical neurons 
[72-74].  
 In addition to the frontal lobe, the amygdala, a region of the brain 
implicated in emotional regulation, memory, and attention, has been associated 
in impulsive-aggressive behavior [77]. With connections to and from the cortical, 
hypothalamic, and brain stem regions, the amygdala is regarded as a filter for 
evaluating the significance of a stimuli and mediating the corresponding 
emotional or behavioral response [78]. It has been suggested that the frontal lobe 
is in direct control of the amygdala and an inverse correlation exists between the 
activity of the frontal lobe and the activity of the amygdala. Two functional 
neuroimaging studies have shown that  in healthy normal subjects of 40 women 
and 14 women and men, respectively, during the suppression of negative 
emotion the activity of the frontal lobe is significantly increased while the activity 
of the amygdala is significantly decreased [79, 80]. Therefore, dysfunction of the 
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frontal lobe may lead to the increased function of the amygdala and the 
amplification of negative emotional responses. In brain studies using functional 
magnetic resonance imaging, borderline personality disorder patients, whom 
commonly exhibit impulsive aggression, were shown to have increased activity in 
the amygdala and greater startle response, in comparison to healthy subjects, 
when presented with stimuli designed to elicit negative emotions (Figure 3 and 
Figure 4) [81-85]. However, when presented with neutral or positive stimuli, the 
activity of the amygdala and the startle response in borderline personality 
disorder patients did not differ from healthy controls [85, 86]. This observed 
pattern of amygdala activity and startle response suggests that impulsive-
aggressive individuals are more susceptible to negative stimuli and may explain 
the difference in resultant behavior between individuals exposed to the same 
conditions and stimuli. 
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A)  
B)  
Figure 3. Functional magnetic resonance imaging (fMRI) of brain regions 
involved in the voluntary regulation of emotion in response to emotionally 
aversive stimuli. A. Bilateral amygdala and fusiform gyrus activation to 
emotionally aversive slides in female patients with borderline personality disorder 
(left) and in normal volunteers (right). Figure taken from Herpertz SC, et al., 
2001. B. Region in which patients with borderline personality disorder showed 
greater activation towards negative pictures than healthy controls. Figure taken 
from Koenigsberg HW, et al., 2009. 
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Figure 4. Means for startle eyeblink modification percent change scores in 
response to neutral and unpleasant word condition in healthy control subjects 
and borderline personality disorder patients. Data adapted from Hazlett EA et al., 
2007. 
 
In conjunction with the decreased activity of the frontal lobe and the 
increased activity of the amygdala, a difference in levels of neurotransmitters has 
been observed in the neural circuitry of impulsive aggression. The frontal lobe 
has been linked to having an inhibitory role on the nucleus accumbens’ 
dopamine release during amygdala activation and the impaired function of the 
frontal lobe would attenuate the inhibition, resulting in increased dopamine 
release [87, 88]. Furthermore, with projections from the amygdala to the locus 
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coeruleus, the hyperactivity of the amygdala is speculated to induce a similar 
increase of activity in the locus coeruleus, thereby elevating levels of released 
catecholamines, specifically dopamine and norephinephrine [89-92]. Combined 
together, the resulting high level of dopamine has been implicated in enhancing 
impulsive-aggressive behavior. From animal studies, increased levels of 
dopamine, ranging from 130% to 170% above baseline levels, corresponded to 
impulsive-aggressive behavior in rats that observed or participated in fighting 
when compared to controls [93-96]. Similarly, in human studies, the 
cerebrospinal fluid concentration of homovanillic acid (HVA), a metabolite of 
dopamine, was detected at higher levels in violent offenders when compared to 
controls [97, 98]. Studies in which dopamine levels were pharmacologically 
altered provide support for the positive correlation between dopamine levels and 
impulsive-aggressive behavior. Administration of substances that elevate 
dopamine concentrations, such as amphetamines, cocaine, alcohol, or dopamine 
agonists, have been linked to increased levels of aggression, as characterized by 
the increase in the frequency of fighting [99-104]. On the other hand, the 
administration of dopamine D2 receptor antagonists, such as antipsychotics 
agents, have been linked to significantly decreased levels of impulsive 
aggression in patients with borderline personality disorder as well as 
schizophrenics, when measured by evaluations such as the Barratt Impulsivity 
Scale, Buss-Durkee Hostility Inventory, and Aggression Questionnaire [105-108]. 
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Considering that the serotonergic system regulates dopaminergic activity 
through reciprocal interaction when the frontal lobe is functioning normally, the 
elevated levels of dopamine observed when the function of the frontal lobe is 
impaired implies a deficiency of serotonergic function during impulsive-
aggressive behavior [109, 110]. Support for this implication was observed in 
animal studies, in which an increase in dopamine levels was mirrored by a 
decrease in serotonin levels during and after an aggressive confrontation, and in 
human studies, in which violent offenders had high levels of dopamine 
metabolites and low levels of serotonin metabolites [94-98]. Therefore, based on 
the genetic inheritability of personality traits and the strength of negative 
correlation between dopamine and serotonin levels, serotonergic dysfunction can 
be considered a neurochemical indicator of impulsive aggression. The validity of 
this consideration has been consistently demonstrated through research in 
animal and human studies. In animal studies, low cerebrospinal fluid (CSF) 
concentrations of the major serotonin metabolite 5-hydroxyindoleacetic acid (5-
HIAA) has been associated with impulsivity, increased violence during 
aggressive behavior, and a higher rate of premature death [111-115]. In human 
studies, summarized in Table 3, lower CSF concentrations of 5-HIAA were found 
in individuals associated with impulsivity or aggression, such as violent offenders, 
arsonists, and individuals with personality disorders, when compared to controls. 
The lowest CSF concentrations of 5-HIAA, however, were observed in individuals 
associated with both impulsivity and aggression, thereby suggesting serotonergic 
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dysfunction is most severe during impulsive aggression [116-122]. In addition, 
the pharmacological manipulation of the serotonin receptors 5-HT1A and 5-HT1B 
has been shown to play a role in modulating aggression. In mice, the direct or 
systemic administration of 5-HT1A and 5-HT1B receptor agonists, such as 8-OH-
DPAT and CP-94253, into the brain effectively decreased forms of aggressive 
behavior, such as the frequency of attack bites and pursuits, while the co-
administration of 5-HT1A and 5-HT1B receptor antagonists, such as GR-127935 
and WAY-100635, blocked these aggression-inhibiting effects [123-132]. 
Emphasis has been placed on the role of 5-HT1B receptors in mediating 
aggression and impulse control. In studies comparing mutant mice lacking the 5-
HT1B receptor with wild type mice, isolated mutant mice displayed more 
behavioral disinhibit ion by attacking intruder mice with higher frequency and 
intensity than wild type mice [133-135]. Furthermore, the degree of serotonergic 
activity can be indirectly measured through serum levels of prolactin, a pituitary 
hormone that is secreted as serotonin concentration increase [136,137]. Studies 
of central serotonergic function using the administration of fenfluramine 
hydrochloride, a serotonin releasing agent and uptake inhibitor, showed 
significantly blunted prolactin response in patients with impulsive aggressive 
personality disorders when compared to controls, thereby supporting the 
serotonergic deficiency associated with impulsive aggression [138-140]. 
 Overall, these results provide support for a genetic, although it may also 
be acquired, predisposition towards suicide because brain imaging studies of 
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suicide attempters and completers have shown serotonergic abnormalities in the 
frontal lobe similar to those seen during impulsive aggression [141,142]. 
Autoradiographic studies of postmortem tissue from suicide completers have 
suggested the serotonergic dysfunction to be localized in the ventral prefrontal 
cortex based on having the largest change in numbers of presynaptic and 
postsynaptic serotonin receptors. In suicides, the numbers of serotonin 
transporter (5-HTT) sites, which represent the presynaptic serotonin receptors, 
were shown to be reduced while postsynaptic serotonin receptors, such as 5-
HT1A and 5-HT2A, were shown to have increased when compared to controls, 
thereby indicating a reduction of serotonergic neurotransmission (Figure 5, 
Figure 6) [143-148]. The increase in postsynaptic serotonin receptors can be 
viewed as an act of compensatory upregulation in reaction to the decreased 
activity of the serotonin neurons and is supported by a corresponding increase in 
protein and mRNA expression [147]. 
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Figure 5. Mean serotonin transporter (5-HTT) binding in Brodmann areas across 
the prefrontal cortex in suicides and controls. Data adapted from Arango V et al., 
1995 and Mann J et al., 2000.  
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Figure 6. Measures of 5-HT2A receptor mRNA and protein levels in the prefrontal 
cortex, hippocampus, and nucleus accumbens regions of the brain in normal 
subjects (n=15) and suicide victims (n=15). Data adapted from Pandey GN et al., 
2002. 
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In addition, since the act of suicide can be considered an act of self-
directed aggression, if a correlation existed between impulsive aggression and 
suicide, then the degree of lethality in a suicide attempt should be proportional to 
the degree of impulsivity or aggression which can be measured by the level of 
serotonergic deficiency. Studies of cerebrospinal fluid concentrations of 5-HIAA 
in suicide attempters have shown lower concentrations in impulsive violent 
attempters compared to nonimpulsive violent attempters as well as lower 
concentrations in high lethality suicide attempts compared to low lethality suicide 
attempts (Table 3) [148-150]. The similarity in decreased serotonin levels 
observed in suicide and impulsive aggression suggest the possibility that 
serotonergic dysfunction of the frontal lobe may serve as shared mechanism for 
the pathogenesis of these two behaviors. Serotonergic dysfunction of the frontal 
lobe by itself, however, is not enough to explain the pathophysiology of suicide. 
Therefore, additional insight into neurological mechanisms that predispose 
individuals into committing suicide may be gained by studying impulsive 
aggression from the perspective of its relationship with major risk factors of 
suicide, such as depression and chronic stress.  
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Table 3. Mean Serotonin Levels in Subjects and Controls According to Individual 
Studies. 
Author Subjects : Number Mean 5-HIAA levels 
Virkkunen M et al., 
1987 
Arsonists : 20 48.52 ± 18.19 nmol/L 
Violent Offenders : 20 68.05 ± 16.19 nmol/L 
Controls : 10 90.00 ± 29.00 nmol/L 
Virkkunen M et al., 
1996 
Violent crime or fire setter recidivists : 28 50.8 ± 21.7 pmol/L 
Violent crime or fire setter nonrecidivists : 83 72.5 ± 29.9 pmol/L 
Virkkunen M et al., 
1994 
Antisocial Personality Disorder : 23 52.5 ± 25 pmol/mL 
Intermittent Explosive Disorder : 20 52.5 ± 25 pmol/mL 
Nonimpulsive Offenders : 15 87.5 ± 17.5 pmol/mL 
Violent offender suicide attempters : 25 58.8 ± 25.2 nmol/L 
Control Subjects : 21 65 ± 20 pmol/mL 
Cremniter D et al., 
1999 
Impulsive Violent Suicide Attempters : 14 51 ± 41.9 nmol/L 
Nonimpulsive Violent Suicide Attempters : 9 92.4 ± 47.3 nmol/L 
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Healthy Control Subjects : 23 107.3 ± 57.7 nmol/L 
Linnoila M et al., 
1983 
One time violent crime offender 87.1 ± 23.7 nmol/L 
Multiple time violent crime offender 67.9 ± 12.2 nmol/L 
Impulsive violent offender with suicide 
attempts : 17 
67.4 ± 19.7 nmol/L 
Impulsive violent offender without suicide 
attempts : 19 
91.2 ± 22.0 nmol/L 
Traskman L et al., 
1981 
Suicide attempters by intoxication or single 
wrist cut : 22 
92.2 ± 27.1 nmol/L 
Depressed suicide attempters : 8 74.5 ± 19.8 nmol/L 
Nondepressed suicide attempters : 22 89.0 ± 28.0 nmol/L 
Suicide by other methods : 8 65.6 ± 11.2 nmol/L 
Healthy controls : 45 103.6 ± 38.3 nmol/L 
 
 The comorbidity of impulsive aggressive behavior and depression in 
suicide has long been recognized by the psychiatric community. Individually, 
impulsive aggressive behavior and depression are not direct predictors of 
suicide, however, when comorbid, results in a higher mortality risk for suicide. 
Case studies of patients with comorbid borderline personality disorder and 
depression showed the highest degree of lethality and the highest number of 
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suicide attempts when compared to other subgroups of patients, such as patients 
with other personality disorders, and controls (Table 4) [151-156]. This 
synergistic increase in mortality rate, due to comorbidity, may be attributed to the 
combined utilization of the same neurological mechanisms responsible for the 
causation of suicide.  
 
Table 4. Suicide attempt characteristics among patients with borderline 
personality disorder, major depressive episode, or both disorders. Data adapted 
from Soloff PH et al., 2000. 
Characteristic of Suicide 
Attempts 
Borderline 
Personality 
Disorder 
(n=25) 
Borderline Personality 
Disorder Plus Major 
Depressive Episode (n=43) 
Major Depressive 
Episode (n=27) 
Number of lifetime 
attempts, covaried for age 
2.5 ± 1.8 3.4 ± 2.4 2.3 ± 1.6 
Scores on measures derived 
from Suicide Intent Scale     
   Lethal Intent     
      Most recent attempt 7.9 ± 3.8 8.8 ± 2.9 8.0 ± 3.3 
      Lifetime 7.8 ± 4.0 9.5 ± 2.5 8.0 ± 4.1 
   Objective planning     
      Most recent attempt 5.4 ± 3.5 7.6 ± 3.3 7.3 ± 3.5 
      Lifetime 5.0 ± 3.4 8.0 ± 2.9 6.4 ± 3.9 
Maximum score on Medical 
Lethality Scale   
  
   Most recent attempt 2.6 ± 2.3 3.1 ± 1.9 2.3 ± 2.4 
   Lifetime 3.5 ± 1.9 3.9 ± 1.6 2.8 ± 2.3 
 
One neuroanatomical abnormality that has been implicated through the 
use of fenfluramine, in the comorbidity of impulsive aggressive behavior and 
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depression, is the serotonergic dysfunction of the frontal lobe. Fenfluramine, a 
serotonin releasing agent and uptake inhibitor, is a chemical agent that 
stimulates the release of serotonin, which in turn exerts regulatory control over 
the secretion of pituitary hormones such as prolactin. The plasma levels of these 
pituitary hormones may serve as an indicator of serotonin responsitivity and is 
widely used to evaluate serotonergic function. Studies of central serotonergic 
function using fenfluramine challenge had shown significantly lower prolactin 
response in depressed patients when compared to controls (Table 5) [157-161]. 
These results are consistent with the blunted prolactin response to fenfluramine 
challenge in patients with impulsive aggressive personality disorders (Table 5) 
[138-140]. Further studies of fenfluramine challenge in depressed patients have 
revealed a potential explanation for the increased mortality rate associated with 
the comorbidity of impulsive aggressive behavior and depression. Significantly 
lower prolactin response to fenfluramine was observed in patients with a history 
of suicide attempts compared to patients without a history of suicide attempts, 
thereby suggesting another source of serotonergic dysfunction was needed in 
conjunction with depression to induce suicidal behavior (Table 5) [162, 163]. 
 
Table 5. Prolactin Response to Fenfluramine in Subjects and Controls According 
to Individual Studies. 
Author Subjects : Number Prolactin response to fenfluramine 
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Sher L et al., 2003 
Unipolar depression : 158 53.3 ± 34.0 (hours x ng/ml) 
Bipolar depression : 21 49.8 ± 28.4 (hours x ng/ml) 
Healthy controls : 32 64.6 ± 25.0 (hours x ng/ml) 
Siever LJ et al., 1999 
Impulsive-aggressive patients : 6 10.9 ± 11.0  
Normal volunteers : 5 11.0 ± 7.0  
Coccaro EF et al., 1989 
Depressed patients with major 
affective disorder and suicide 
attempts : 7 
5.9 ± 2.9  
Depressed patients with 
personality disorder and suicide 
attempts : 7 
5.0 ± 3.3 
Depressed patients with major 
affective disorder and no suicide 
attempts : 18 
10.0 ± 7.0  
Depressed patients with 
personality disorder and no suicide 
attempts : 13 
9.1 ± 5.5  
 
The serotonergic dysfunction associated with impulsive aggressive 
behavior holds the potential to account for the serotonergic difference between 
depression and suicidal behavior. In a fenfluramine challenge study of depressed 
patients, significantly blunted prolactin response was observed in depressed 
patients with anger attacks when compared to patients without anger attacks 
(Figure 7) [164]. The extra serotonergic dysfunction in depressed patients 
induced by impulsive aggression may represent the observed serotonergic 
difference, between patients with a history of suicide attempts and patients 
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without such a history, and justify the increased mortality rate for suicide when 
depression and impulsive aggressive behavior are comorbid.  
 
 
Figure 7. Prolactin response to DL-fenfluramine minus placebo in patients with 
and without anger attacks (AA). Data adapted from Fava M et al., 2000. 
 
In addition to the serotonergic dysfunction of the frontal lobe, other 
neuroanatomical abnormalities shared by impulsive aggressive behavior and 
depression include the volumetric reduction of the hippocampus and amygdala.  
Magnetic resonance imaging studies of patients with borderline personality 
disorder showed significant reductions in hippocampal and amygdala volumes 
when compared to controls (Table 6) [165-171]. Similar reductions were 
observed in patients with major depressive disorder (Table 6) [172-178]. Results 
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from dexamethasone and corticotrophin-releasing hormone challenge studies 
suggest the morphological changes are induced by a hyperactive HPA axis. 
Similar to fenfluramine challenge studies, dexamethasone and corticotrophin-
releasing hormone are administered to stimulate the release of ACTH and 
cortisol, which are used to evaluate HPA activity. In their respective studies, 
patients with major depression and patients with borderline personality disorder 
showed significantly enhanced corticotrophin and cortisol response, meaning 
higher levels of ACTH and cortisol, when compared to controls [179-182]. A 
study in particular, showed higher responses to dexamethasone and 
corticotrophin-releasing hormone in depressed patients with a history of 
attempted suicide compared to depressed patients without such a history (Table 
7), thereby suggesting a difference in HPA axis activity that can potentially be 
accounted for by the comorbidity of depression and impulsive aggressive 
behavior [182]. 
 
Table 6. Mean Hippocampal and Amygdalar Volumes in Subjects and Controls 
According to Individual Studies. BPD = Borderline Personality Disorder. PTSD = 
Post Traumatic Stress Disorder. 
Author Subjects : Number Mean Hippocampal Volume Mean Amygdalar Volume 
Schmahl et al., 
2003 
Patients with BPD : 
10 
Left side : 2120 ± 416 mm3 Left side : 1665 ± 384 mm3 
Right side : 1883 ± 286 mm3 Right side : 1661 ± 371 mm3 
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Controls : 23 
Left side : 2380 ± 811 mm3 Left side : 2167 ± 727 mm3 
Right side : 2244 ± 768 mm3 Right side : 2090 ± 723 mm3 
Tebartz an Elst 
L et al., 2003 
Patients with BPD : 8 
Left side : 2.82 ± .15 cm3 Left side : 1.6 ± .11 cm3 
Right side : 3.07 ± .18 cm3 Right side : 1.6 ± .1 cm3 
Healthy Controls : 8 
Left side : 3.55 ± .29 cm3 Left side : 2.1 ± .14 cm3 
Right side : 3.89 ± .37 cm3 Right side : 2.15 ± .14 cm3 
Weniger G et 
al., 2009 
Patients with BPD 
and PTSD : 10 
Left side : 2.49 ± 0.41 mL Left side : 0.72 ± 0.19 mL 
Right side : 2.54 ± .46 mL Right side : 0.77 ± .14 mL 
Patients with BPD 
without PTSD : 14 
Left side : 2.68 ± 0.37 mL Left side : 0.90 ± .27 mL 
Right side : 2.84 ± .43 mL Right side : 0.89 ± .24 mL 
Controls : 25 
Left side : 2.95 ± 0.43 mL Left side : 1.12 ± 0.15 mL 
Right side : 3.16 ± .35 mL Right side : 1.15 ± .16 mL 
Sala M et al., 
2010 
Patients with BPD : 
15 
Left side : 1.23 ± 0.23 mL N/A 
Right side : 1.24 ± .26 mL N/A 
Controls : 15 
Left side : 1.27 ± 0.22 mL N/A 
Right side : 1.42 ± .15 mL N/A 
Kronenberg G 
et al., 2010 
Depressed patients : 
15 
N/A Left side : 1.71 ± 0.34 mL 
N/A Right side : 1.74 ± 0.27 mL 
Controls : 15 
N/A Left side : 1.97 ± 0.26 mL 
N/A Right side : 1.97 ± .28 mL 
Sheline YI et 
al., 1996 
Depressed patients : 
10 
Left side : 2159 ± 301 mm3 N/A 
Right side : 2283 ± 324 mm3 N/A 
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Controls : 10 
Left side : 2544 ± 333 mm3 N/A 
Right side : 2577 ± 259 mm3 N/A 
 
Table 7. Adrenocorticotropic hormone (ACTH) and cortisol response to 
Dexamethasone (DEX) / corticotrophin releasing hormone (CRH) in suicidal and 
non-suicidal patients with major depression. BASAL concentrations were defined 
as the plasma concentration after DEX administration but before infusion of CRH. 
MAX concentration was defined as the maximum values observed. DELTA 
values were the difference between MAX and BASAL values. A.U.C is defined as 
the area under curve. Data adapted from Kunugi H et al., 2004.  
ACTH response to DEX/CRH 
(pg/ml) BASAL MAX DELTA A.U.C 
Suicidal patient with major 
depression (n=7) 
11.1 ± 
5.5 
55.1 ± 
42.2 
44.0 ± 
38.0 
2657 ± 
2027 
Non-suicidal patient with 
major depression (n=13) 
5.3 ± 
4.4 
23.9 ± 
19.1 
18.6 ± 
16.7 
1318 ± 
1102 
Cortisol response to 
DEX/CRH (ug/dl) BASAL MAX DELTA A.U.C 
Suicidal patient with major 
depression (n=7) 
3.3 ± 
2.4 
12.7 ± 
5.8 9.4 ± 4.5 694 ± 352 
Non-suicidal patient with 
major depression (n=13) 
1.7 ± 
1.4 6.9 ± 5.7 5.2 ± 4.7 355 ± 329 
 
 In comparison to depression, the biochemical and neuroanatomical 
changes induced by chronic stress have also been recognized to be associated 
with impulsive aggression in the causation of suicidal behavior. Functional 
neuroimaging studies of animals and humans have localized the effects of 
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chronic stress to regional areas of the brain. In animal studies, rats that have 
been subjected to chronic stress in the form of daily restraint showed significant 
dendritic atrophy, represented by decreased grey matter volume, in the medial 
prefrontal cortex and hippocampus [183-187]. The decrease in grey matter 
volume was the result of shorter dendritic branches and fewer dendritic branch 
points. In human studies using magnetic resonance imaging, patients with post-
traumatic stress disorder showed significantly reduced grey matter volume in the 
medial prefrontal cortex, hippocampus, and amygdala when compared to 
controls [188-195]. Therefore, based on similarities between the neuroanatomical 
abnormalities associated with impulsive aggression and chronic stress, the 
hyperactivity of the HPA axis has been implicated as one of the neurological 
mechanisms responsible for the causation of suicide. As a result, the 
independent HPA activity induced by chronic stress and impulsive aggressive 
behavior may combine together in a synergistic manner to reach the 
characteristic levels of elevated HPA axis activity observed in individuals who 
attempted suicide. 
 The finding of a difference in serotonergic dysfunction and HPA axis 
activity between individuals with a history of suicide attempts and individuals 
without such a history suggests that suicidal behavior is strongly associated with 
impulsive aggression, depression, and chronic stress. However, the individual 
contribution from impulsive aggression, depression, and chronic stress to the 
level of serotonergic dysfunction and HPA axis activity in an individual has been 
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shown to be below the levels observed in suicide attempters. Therefore, the 
increased mortality rate associated with the combination of impulsive aggression 
and depression or chronic stress (Table 5) suggest that suicide most likely 
occurs when individuals with impulsive aggressive personalities suffer from a 
psychiatric illness, such as depression, or a significant life stressor, during which 
the individual contributions of serotonergic dysfunction and HPA axis activity 
combine together in synergistic effect to result in an enhanced level of 
serotonergic dysfunction and HPA axis activity that is similar to the levels seen 
during suicidal behavior . This enhanced level of serotonergic dysfunction and 
HPA axis activity is characterized by the same accompanying neuroanatomical 
abnormalities of volumetric reductions in the frontal lobe, hippocampus, and 
amygdala. 
  
Neuronal Plasticity and Suicidal Behavior 
Over the past two decades, studies in neuronal function have led to an 
evolving hypothesis that suggested a role of neuronal plasticity in the 
pathophysiology of suicidal behavior. The two processes that characterize 
neuronal plasticity, neurogenesis and neuronal remodeling, help the brain 
maintain homeostasis by regulating the proliferation, migration, and 
differentiation of new neurons into the neural circuits. For example, animal 
studies have shown experimental evidence of the role neurogenesis plays in 
formation and retention of memory. Animals irradiated to induce a state of 
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reduced neurogenesis showed deficits in spatial memory task performance and 
memory retention when compared to non-irradiated animals due to the fact that 
the irradiated animals had far fewer neurons to develop memory stability during 
the training period. [196]. The process of neurogenesis and neuronal remodeling  
are mediated by neurotrophic factors such as neurotrophins, glial cell-line derived 
neurotrophic factor, and neuropoietic cytokines. Neurotrophins, with brain-
derived neurotrophic factor (BDNF) in particular, have been identified as the 
molecular mediators of synaptic and morphological plasticity responsible for the 
regulation, differentiation, and maintenance of functions in neurons [197-201]. 
For example, the involvement of BDNF in neuronal plasticity has been observed 
in the studies examining the visual cortex of animal subjects in vivo. During 
critical periods of development, when the visual input is blocked by monocular 
deprivation, the connectivity in the visual cortex of animals can be altered by 
rendering neurons nonresponsive to stimuli in the deprived eye. However, the 
local administration of BDNF into the visual cortex of the animal subjects during 
the critical period of development prevented the effects of monocular deprivation 
and maintained responsiveness in the deprived eye. [197]  Therefore, in the 
event that neuronal plasticity becomes impaired, the brain fails to adapt and 
maintain homeostasis, thereby leading to the development of neuroanatomical 
abnormalities and functional impairments that contribute to the expression of 
suicidal behavior. Therefore, to evaluate the role of neuronal plasticity in the 
pathophysiologic mechanism of suicide, the involvement of BDNF will be 
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considered in the context of major risk factors of suicide, such as chronic stress 
and depression. 
The effect of stress on the neuroanatomical structures related to suicidal 
behavior has long been recognized through animal and human studies. Subjects 
exposed to chronic stress are characterized by volumetric reductions of the 
frontal lobe, hippocampus, and amygdala [183-195]. These volumetric 
reductions, in the form of dendritic reduction and atrophy, indicate a failure of 
BDNF to maintain homeostasis. In animal studies, when rats were initially 
subjected to stress, a transient increase in BDNF expression was observed in 
structures of the brain, such as the hippocampus, pituitary gland, and 
hypothalamus, thereby suggesting a short-term preventative mechanism against 
dendritic damage by promoting cell growth and survival [202-206]. However, after 
the transient increase in BDNF expression, during acute and chronic stress the 
expression of BDNF mRNA is dramatically downregulated and accompanied by 
volumetric reductions in the hippocampus and frontal lobe [207-211]. In 
pharmacological tests in which rodents were injected with exogenous 
glucocorticoids, to mimic the effect of stress, the expression of BDNF was shown 
to be reduced in the hippocampus and frontal lobe [206, 212, 213]. The 
downregulation of BDNF mRNA is further supported by the observed increase in 
the BDNF receptor tyrosine kinase B (trk B) mRNA which serves as a 
compensatory adaptation to low levels of BDNF [214]. Therefore, by 
downregulating the expression of BDNF mRNA, stress has been shown to 
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contribute to the dendritic atrophy and decreased neurogenesis of areas in the 
brain associated with deterring suicidal behavior. 
The relationship between BDNF and depression has also been 
demonstrated through brain imaging and postmortem studies of depressed 
patients. Volumetric reduction of the hippocampus, frontal lobe, and amygdala 
has been observed in patients with depression, indicating a failure of BDNF to 
maintain homeostasis. The decreased neuronal body size and glia cell density 
associated with the volumetric reductions, seen in depressed patients (Table 8),  
demonstrated the inability of BDNF to prevent atrophy or stimulate neurogenesis, 
which can be attributed to decreased levels of BDNF [215-217]. 
 
Table 8. Layer-specific mean neuron size and mean glial densities in the left 
rostral orbitalfrontal cortex, left caudal orbitofrontal cortex, and dorsal lateral 
prefrontal cortex in psychiatrically normal controls and patients with major 
depression. Mean neuron size are described in 4 x (Area/Circumference) μm. 
Mean glial density are described in # of cells / (mm3 x 10-3 μm). Data adapted 
from Rajkowska G et al., 1999. 
Psychiatrically Normal Controls (n=12) Mean Neuron Size Mean Glial Density 
Left Rostral Orbitofrontal Cortical Region 12.9 ± 0.6 110 ± 17 
Left Caudal Orbitofrontal Cortical Region 12.6 ± 0.6 105 ± 7 
Dorsolateral Prefrontal Cortical Region 13.4 ± 0.9 100 ± 13 
Patients with Major Depression (n=12) Mean Neuron Size Mean Glial Density 
Left Rostral Orbitofrontal Cortical Region 12.3 ± 0.5 100 ± 17 
Left Caudal Orbitofrontal Cortical Region 12.2 ± 0.5 91 ± 14 
Dorsolateral Prefrontal Cortical Region 12.8 ± 0.6 92 ± 9 
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 The usage of antidepressant treatments, however, can reverse these 
volumetric reductions and has been implicated in the modulation of BDNF 
expression. The chronic treatment using antidepressants has been shown to 
increase neurogenesis by increasing BDNF expression in the hippocampus and 
prefrontal cortex of rats (Figure 8) [218-220]. Rats chronically treated with 
duloxetine showed significantly higher levels of BDNF in the cerebral spinal fluid 
and prefrontal cortex when compared to control and vehicle-treated rats. 
Antidepressant treatment has also been shown to reverse the downregulation of 
neurogenesis caused by depression and stress. In studies using serotonin 
knockout rats to simulate the effects of depression, the chronic administration of 
duloxetine normalized or increased the naturally reduced expression of BDNF 
mRNA in the hippocampus and prefrontal cortex (Figure 9) [221, 222]. Similarly, 
in studies employing various forms of stress, the chronic administration of 
antidepressant drugs, such as venlafaxine and imipramine, was shown to 
enhance the rate of recovery in levels of BDNF when compared to the chronic 
administration of saline or nothing at all. [223, 224]. Based on these findings, the 
reduced expression of BDNF can be implicated in having a key role in the 
development of depression, which can eventually contribute to the suicidal 
behavior. 
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Figure 8.Total BDNF levels in the cerebral spinal fluid (CSF) and prefrontal 
cortex (PFC) of untreated rats (controls), vehicle-treated rats, and duloxetine 
treated (100 mg/kg/day) rats over the period of 14 days. Data adapted from 
Mannari C et al., 2008. 
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Figure 9. Total BDNF mRNA levels in the hippocampus, prefrontal cortex (PFC), 
and frontal cortex (FC) of wild type (WT) and serotonin transporter knockout (KO) 
rats after long term (21 days) treatment with vehicle or duloxetine and killed 24 
hours after last injection. BDNF mRNA levels are expressed as a percentage of 
the WT/Vehicle mean (set as 100%). Data adapted from Calabrese F et al., 
2010. 
 
Therefore, due to the role of neurotrophins in the maintenance of neuronal 
functions, structural integrity of neurons, and neurogenesis, a detectable 
variation in the endogenous levels of BDNF may be of forensic significance for 
medical examiners. In consideration of the fact that depression and stress are 
recognized components of suicide and proven to influence the down regulation of 
BDNF expression, it would be rational to assume that a lower level of BDNF 
expression would be associated with suicide. Support for this association can be 
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found in post-mortem studies of suicide subjects. In fact, several studies have 
shown significant differences in mRNA and protein levels of BDNF and trk B 
within the brain of suicide victims in comparison to control subjects [225-227].In 
each of these studies, the protein and mRNA expression of BDNF and trk B were 
determined and shown to be significantly decreased in the prefrontal cortex and 
hippocampus of suicide completers when compared to healthy controls (Table 9). 
The decreased protein level of BDNF was strongly correlated with its 
corresponding mRNA level, thereby suggesting less BDNF synthesis in the 
brains of suicide subjects. A study in particular, suggests the decrease in BDNF 
levels was only limited to areas of the brain associated with emotional control. In 
the study of BDNF expression in the prefrontal cortex, hippocampus, and 
entorhinal cortex of suicide subjects, significantly decreased levels of BDNF were 
only found in the prefrontal cortex and hippocampus (Figure 10) [227]. 
Furthermore, a study of patients with major depressive disorder has shown that 
levels of plasma BDNF were significantly lower in suicidal patients (430.5 ± 397.0 
pg/mL) when compared to non-suicidal patients (875.80 ± 663.02 pg/mL) and 
controls (889.4 ± 611.3 pg/mL) [228]. The reduced plasma BDNF levels were no 
different between fatal and non-fatal suicide attempts, indicating an enhanced 
state of BDNF deficiency, compared to the BDNF deficiency of non-suicidal 
depressed patients, is required for suicidal behavior. Overall these findings 
suggest that BDNF is involved in the pathophysiology of suicidal behavior. 
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Table 9. Mean levels of messenger RNA (mRNA) and protein expression of 
BDNF and trk B in the prefrontal cortex and hippocampus of control subjects and 
suicide subjects. Data adapted from Dwivedi Y et al., 2003. 
Mean Values of BDNF and 
trk B mRNA and protein Prefrontal Cortex Hippocampus 
Variable 
Control 
Subjects 
(n=21) 
Suicide 
Subjects 
(n=25) 
Control 
Subjects 
(n=21) 
Suicide 
Subjects 
(n=25) 
BDNF mRNA (attomole 
per microgram of total 
RNA) 
606.8 ± 
139.5 
359.6 ± 
96.7 
2049.4 
± 642.8 
1161.35 
± 286.5 
BDNF protein (arbitrary 
units) 
1.61 ± 
0.39 
0.91 ± 
0.25 
1.71 ± 
0.44 
1.04 ± 
0.21 
trk B mRNA (attomole per 
microgram of total RNA) 
1168.3 
± 322.3 
704.5 ± 
225.7 
1325.4 
± 401.7 
798.85 
± 314.2 
Full length trk B protein 
(arbitrary units) 
1.29 ± 
0.31 
0.87 ± 
0.19 
1.59 ± 
0.42 
0.9 ± 
0.31 
Truncated trk B protein 
(arbitrary units) 
1.36 ± 
0.32 
1.44 ± 
0.27 
1.59 ± 
0.36 
1.52 ± 
0.27 
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Figure 10. Mean values of BDNF protein in the hippocampus, prefrontal, and 
entorhinal cortex from non-suicidal controls and 3 groups of suicide victims. 
Figure adapted from Karege F et al., 2005.
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4.3. Consideration of Hypotheses of Suicide Pathophysiology and 
Suggested Guideline for Classifying Manner of Death 
 
 When comparing the viability of the two hypotheses of suicide 
pathophysiology, the similarity in neuroanatomical abnormalities and functional 
impairments, in relation to depression, chronic stress, and postmortem studies, 
suggests the possibility of the two hypotheses being interrelated and 
interconnected. The enhanced state of BDNF deficiency observed in suicidal 
patients of major depressive disorder, compared to non-suicidal patients, may be 
explained by the increased reactivity and response to stress and depression by 
individuals with impulsive aggressive personality traits. Likewise, the increased 
response to stress and depression in suicidal individuals with impulsive 
aggressive personality traits may be attributed to the enhanced susceptibility to 
serotonergic dysfunction and HPA axis activity generated from the failure of 
BDNF to maintain homeostasis. Therefore, in consideration of formulating a 
comprehensive method to differentiate biological markers of suicidal behavior 
from the usual neuroanatomical alterations associated with depression and 
chronic stress, the significant differences observed in suicidal subjects from the 
two hypotheses of suicide pathophysiology will be integrated into one diagnostic 
guideline. Based on the experimental evidence from multiple studies, these 
significant differences include an enhanced state of serotonergic dysfunction, 
HPA axis activity, and BDNF deficiency. The forensic applicability in detecting 
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and measuring these differences in post-mortem samples will be discussed in the 
paragraphs that follow. The guideline for the new proposed form of diagnosing 
suicidal behavior is an adaption of autopsy practices and procedures from 
studies that have shown successful extraction and quantitation of molecules of 
interest. The guideline is not meant to replace the findings from a scene 
investigation nor background history. Taken into consideration independently, the 
results from this guideline will only suggest if the decedent was in a suicidal state 
of mind.  
 
Postmortem Brain Collection and Processing 
 Upon reaching the stage of the autopsy to examine the brain, the hair 
should be separated and an incision should be made, from ear to ear, across the 
vertex of the scalp. The scalp should then be reflected and another incision 
should be made to reflect the temporalis muscle. Using an oscillating saw, the 
calvarium should be cut and the skull cap should be detached from the dura. 
Next, the superior longitudinal sinus is to be opened and the dura along the cut 
on the skull should be cut and reflected toward the midline to expose the brain. 
At this point, the brain is to be inspected for any trauma or anatomical 
abnormalities. The frontal poles are then to be retracted and the anterior 
attachments of falx cut. Afterwards, the olfactory bulbs are to be elevated and the 
brain retracted to expose the optic nerves, carotid arteries, and any other 
attached nerves which are to be cut. The brain is then to be retracted medially, 
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so the tentorial attachments along the petrous ridges can be cut, and then 
retracted posteriorly, so the spinal cord and any remaining cranial nerves or 
vertebral arteries can be cut as distally as possible. Finally, the cerebellum and 
brainstem is to be retracted in order to cut any remaining dura that may be 
keeping the brain still attached to the skull [229].  
Following the removal of the brain, sections of the prefrontal cortex and 
hippocampus are to be dissected from the right hemisphere of the brain. The 
right hemisphere of the brain was selected because structural abnormalities in 
the area have been shown to be associated with antisocial, violent, and suicidal 
behavior [230, 231]. The prefrontal cortex is to be considered the gray matter 
from the most anterior 1-cm coronal slice of the cortex and a block of tissue is to 
be dissected from Brodmann area 9 according to a Brodmann atlas. This isolated 
piece of tissue is to be stored at -80 °C until finer dissection is required. When 
the time comes for finer dissection, the tissue is to be thawed from -80 °C to -20 
°C, placed onto a glass surface with dry ice, and dissected to isolate 0.5- to 1-cm 
coronal slices of gray matter without the incorporation of any white matter. The 
distinction between gray and white matter is important during dissection because 
gray matter is composed of cell bodies while white matter is composed of nerve 
fibers. For the hippocampus, 0.5-cm coronal slices of gray matter, without the 
incorporation of white matter, are to be dissected from the middle of the 
hippocampus and should include the dentate gyrus and areas of CA1-4. If these 
isolated samples of tissue are not to be used immediately, they should be stored 
57 
 
at -80°C. When the time comes to test the tissue samples, the individual pieces 
from the prefrontal cortex and hippocampus should be homogenized separately 
with a tissue grinder using appropriate buffer solutions. Although the amygdala 
has been implicated in serotonergic dysfunction and HPA axis activity, studies of 
the amygdala in the context of suicidal behavior is limited therefore the analysis 
of the amygdala will be excluded from this guideline. These procedures for 
analyzing the prefrontal cortex and hippocampus were adapted from studies that 
have successfully quantitated serotonin, BDNF, and trk B in suicide victims. 
Factors such as post-mortem interval, sex, age, and brain pH were not shown to 
have any significant effect on the outcome the analysis and were excluded during 
consideration.  
 
Quantification of Serotonergic Dysfunction 
 As the studies have shown, serotonergic dysfunction is associated with 
low CSF concentrations of serotonin and serotonin metabolite 5-HIAA, elevated 
dopamine levels, low prolactin levels during a fenfluramine challenge, volumetric 
reduction of the prefrontal cortex, a reduced number of presynaptic serotonin 
receptors, and an increased number of postsynaptic serotonin receptors. 
However, the quantitation and comparison of all these differences may not be a 
viable option during an autopsy exam. CSF concentrations of serotonin, 5-HIAA, 
and dopamine are known to fluctuate throughout the day and are immediately 
increased by alcohol, drugs, and antidepressant use. In deaths due to 
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drug/ethanol overdose, the CSF concentrations of serotonin, 5-HIAA, and 
dopamine would be skewed and an inaccurate representation of the level of 
serotonergic dysfunction. The alternative options of measuring prolactin levels 
during a fenfluramine challenge or measuring the volumetric reduction in the 
prefrontal cortex are also unfeasible options since the tests are required to be 
performed in vivo. The only potential candidates able to represent serotonergic 
dysfunction are the reduced number of presynaptic serotonin receptors and the 
increased number of postsynaptic serotonin receptors. Unlike CSF 
concentrations of serotonin and 5-HIAA, serotonin receptors are less susceptible 
to change in the presence of drugs and alcohol and offer a more reliable 
representation of the degree of serotonergic dysfunction. Therefore, mRNA and 
proteins levels of presynaptic serotonin transporter sites and post synaptic 5-
HT2A and 5-HT1A receptors should be quantified using competitive reverse 
transcriptase-polymerase chain reaction (RT-PCR) and Western blot analysis, 
respectively, and compared to values from depressed patients and healthy 
controls. An individual in a suicidal state of mind would show significantly 
decreased mRNA and protein levels of presynaptic receptors along with 
significantly increased mRNA and protein levels of postsynaptic receptors in the 
prefrontal cortex, when compared to depressed patients and healthy controls.  
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Quantification of HPA Axis Hyperactivity 
In contrast, the hyperactivity of the HPA axis is associated with low CSF 
concentrations of serotonin, high CSF concentrations of dopamine, epinephrine 
and norepinephrine, high cortisol response during a dexamethasone and 
corticotrophin releasing hormone challenge, and volumetric reduction of the 
prefrontal cortex and hippocampus. Similar to serotonergic dysfunction, the CSF 
concentrations of serotonin, dopamine, epinephrine, and norepinephrine during 
HPA axis hyperactivity are affected by alcohol, drug, and antidepressant usage 
and are unreliable markers of the degree of HPA axis hyperactivity. In addition, in 
cases of chronic stress, the concentrations of dopamine, epinephrine, and 
norepinephrine are constantly changing as they shift from elevated levels to 
decreased levels as the monoamine stores become depleted due to the 
prolonged HPA axis activity. The alternative options of measuring cortisol 
response during a dexamethasone and corticotrophin releasing hormone 
challenge or measuring the volumetric reduction in the prefrontal cortex and 
hippocampus are also unfeasible options since the tests are required to be 
performed in vivo and because there are currently no viable means to measure 
this difference during autopsy.  
 
Quantification of BDNF Deficiency 
 BDNF deficiency, on the other hand, has been associated with volumetric 
reductions of the frontal lobe and hippocampus, low levels of BDNF in the blood, 
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and decreased protein and mRNA expression of BDNF and trk B in the prefrontal 
cortex and hippocampus. Similar to the other models, the measurement of the 
volumetric reductions of the frontal lobe and hippocampus is an unfeasible option 
since the procedure requires it to be performed in vivo. Unlike with monoamines, 
the usage of alcohol, drugs, and antidepressants does not immediately alter the 
levels of BDNF in the plasma, serum, or platelet, therefore the low concentrations 
of BDNF in the blood may hold potential in serving as a marker of BDNF 
deficiency. Strenuous exercise has been shown to immediately increase the 
levels of BDNF in the blood, but that level of physical activity is not commonly 
associated with casualties due to drug/ethanol overdose [232, 233]. Decreased 
protein and mRNA expression of BDNF and trk B in the prefrontal cortex and 
hippocampus may also serve as potential markers of BDNF deficiency. However, 
caution should be exercised when dealing with drug/ethanol overdoses that 
involve chronic abuse; studies have shown significant reductions in serum BDNF 
levels in patients with alcohol dependence [234, 235]. Therefore, to diagnosis an 
enhanced state of BDNF deficiency that is suggestive of suicidal behavior, the 
serum BDNF levels should be compared to patients with depression and healthy 
controls. In addition, the mRNA and protein levels of BDNF and trk B receptors 
should be quantified using competitive reverse transcriptase-polymerase chain 
reaction (RT-PCR) and Western blot analysis, respectively, and compared to 
values from depressed patients and healthy controls. An individual in a suicidal 
state of mind would show significantly decreased serum BDNF levels and 
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significantly decreased mRNA and protein levels of BDNF and trk B receptors in 
the prefrontal cortex and hippocampus, when compared to depressed patients 
and healthy controls [225-228].   
 
Quantification of Protein Levels 
 Protein levels are to be measured using the Western blot technique. 
Western blots are routinely used for analyzing protein mixtures and allows for the 
determination of the molecular weight and relative quantity of a specific protein. 
The general process begins with the separation of macromolecules using gel 
electrophoresis and is followed by the transfer of the separated protein pattern 
onto a second matrix which is typically a membrane. The surface of the 
membrane is then treated with generic protein to prevent any nonspecific binding 
of antibodies to the membrane and an enzyme-linked antibody is added to bind 
to the specific protein of interest. Upon the addition of a suitable substrate, the 
enzyme linked to the antibody will produce a product that can be detected and 
measured.    
  
The general steps to quantify protein levels have been summarized in the figure 
below (Figure 11).   
 
 Homogenization of brain tissue  
 
 
 
 Determination of protein concentration using 1-dimensional  
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Western blot 
 
 
 
 Gel electrophoresis  
 
 
 
 Protein pattern on gel transferred to membrane  
 
 
 
 
Incubated with primary antibodies for target proteins (5-HTT, 
5-HT2A, BDNF, trk B)  
 
 
 
 Membrane washed  
 
 
 
 Incubated with β-actin antibodies (used as a loading control)  
 
 
 
 Membrane washed  
 
 
 
 Incubated with secondary antibodies for primary antibody  
 
 
 
 Membrane washed  
 
 
 
 
Membrane developed with chemiluminsecent reagents and 
radiographic film  
 
 
 
 
Determination of the optical densities of target proteins in 
comparison to a reference protein (β-actin)  
   
Figure 11 - Flowchart summary of steps taken to quantify protein 
levels. 
 
Quantification of mRNA levels 
 mRNA levels are to be measured using the competitive reverse 
transcriptase-polymerase chain reaction. Competitive RT-PCR is typically used 
to measure the total amount of a specific mRNA sequence in a sample. The 
process involves combining dilutions of synthesized RNA sequences, which 
serve as internal standards and are identical in sequence but shorter in length 
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than the endogenous mRNA target, with sample RNA replicates before both are 
co-amplified together. The synthesized RNA sequence is capable of being 
amplified by the same primers and with the same efficiency as the target 
endogenous target, therefore it serves to compete with the endogenous mRNA 
transcript during the amplification process. Quantitative measurements of target 
mRNA can then be made by comparing the PCR product signal intensity of the 
endogenous target with the concentration curve generated by the synthetic 
competitor RNA sequence.   
  
The general steps to quantify mRNA levels have been summarized in the figure 
below (Figure 12). 
 
 Homogenization of brain tissue  
 
 
 
 CsCl2 ultracentrifugation  
 
 
 
 
Reverse transcription of internal standards and total RNA with 
reverse transcriptase, primers, water, dNTPs, and RT buffer  
 
 
 
 
PCR amplification of cDNA products from reverse 
transcription  
 
 
 
 
Aliquots of RT-PCR products digested by restriction enzymes 
to cut DNA at specific base sequences of interest  
 
 
 
 Gel electrophoresis  
 
 
 
 Staining of the gel by ethidium bromide  
 
 
 
 Determination of the mRNA levels of target proteins by  
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comparing signal intensity with internal standard 
   
Figure 12 - Flowchart summary of steps taken to quantify mRNA 
levels. 
 
5. CONCLUSIONS 
 
Using an in-depth literature review, the issues contributing to the 
classification of undetermined manner of death were identified and addressed. A 
new guideline, based on scientific studies from the field of neurobiology, was 
formulated to propose an alternative method of diagnosing suicidal behavior in 
order to differentiate between the accidental and suicide manners of death in 
undetermined deaths from drug or ethanol overdose where medical and 
investigational findings are insufficient. The new method of testing differentiated 
between the classification of an accident and a suicide by proving the decedent 
was in a suicidal state of mind, characterized by specific neuroanatomical 
abnormalities observed from post-mortem studies. The predisposition to suicidal 
behavior is established by comparing the degree of serotonergic dysfunction, 
HPA axis activity, and BDNF deficiency observed in an individual to the levels 
observed in patients with depression and healthy normal controls. Based on the 
guideline, an individual in a suicidal state of mind would show significantly 
decreased mRNA and protein levels of presynaptic receptors along with 
significantly increased mRNA and protein levels of postsynaptic receptors in the 
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prefrontal cortex, significantly decreased serum BDNF levels, and significantly 
decreased mRNA and protein levels of BDNF and trk B receptors in the 
prefrontal cortex and hippocampus, when compared to patients with depression 
and healthy controls. The values from suicide subjects were not included for 
comparison because statistical analysis in studies had shown that all the values 
from suicide subjects were significantly lower than the patients with depression 
and healthy controls, therefore any range of determined values which are 
significantly lower than the patients and healthy controls could suggest a similar 
pattern to suicide.  
The burden of the financial costs associated with performing the 
quantitation of both mRNA and protein levels of BDNF, 5-HTT, and 5-HT2A 
receptors, however, may not be welcomed by some medical examiners. The 
equipment and reagents required to quantitate mRNA and protein are costly and 
may exceed the office of the medical examiner’s financial capability. Currently, 
the cost of autopsies are covered by state taxes and the additional cost for 
equipment, training, and reagents, especially in smaller states with a lower 
mortality rate, would be hard to justify. In addition, the extra labor associated with 
the testing would tax the resources and manpower of many offices and create an 
even larger backlog of items that need to be processed. Although these are 
justifiable concerns, it must be taken into consideration that the new form of 
testing is intended to resolve a very specific scenario which could not be resolved 
using the current methods of testing. Depending on the frequency in which 
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medical examiners encounter these scenarios and the amount of third party 
influence, for some medical examiners, the benefits of resolving the classification 
may outweigh the costs 
In order to reduce the financial burden imposed by performing both RT-
PCR and Western blotting to quantitate the mRNA and protein levels in BDNF, 
trk B, 5-HTT, and 5-HT2A receptors, it is suggested that the tests be separated 
into presumptive and confirmatory testing. The levels of serotonin presynaptic 
and postsynaptic receptors, 5-HTT and 5-HT2A respectively, have been shown to 
be altered by the chronic use of SSRIs (selective serotonin reuptake inhibitors) 
[236], while the levels of BDNF and trk B showed no significant difference [230]. 
Therefore, since the quantitation of mRNA and protein levels of 5-HTT and 5-
HT2A is susceptible to the chronic use of SSRIs, the quantitation of mRNA and 
protein levels of BDNF and trk B should serve as the confirmatory diagnosis. By 
separating the testing into presumptive and confirmatory testing, the amount of 
testing and resources required can be reduced to a financially manageable level.     
 In comparison to the current methods used to classify manners of death, 
there are many advantages in adopting this guideline to classify undetermined 
overdose deaths. The main advantage is the ability to produce empirical 
evidence to combat the innate subjectivity of the determination process when 
medical and investigational evidence is lacking. Concerned third parties would no 
longer be able to threaten medical examiners with legal action if a death is 
classified as a suicide because the determination would be based on scientific 
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and medical proof. In addition, the new testing method would be able to resolve 
many of the scenarios that cause ambiguity between an accident or suicide 
classification by being based on something that not readily alterable. Scenarios 
where critical items of evidence go missing or where third parties provide false 
information would not affect the classification as it would in the usual manner. 
The levels of mRNA and protein expression of serotonin receptors, BDNF, and 
trk B in the brain are not easily manipulated and even with the use of drugs, 
alcohol, and anti-depressants, a long period of usage is required before any 
noticeable changes in levels are observed.  
 From a forensic and legal perspective, the new testing method is ideal for 
maintaining chain of custody. The evidence, which is the brain of the decedent, is 
protected by the skull, making it difficult to contaminate or destroy, and only 
trained personnel would be able to harvest the brain. In addition, the brain is 
located far from the effects of decomposition or digestive fluids. In fact, studies 
have also shown that effects such as age, postmortem interval, sex, and brain 
pH have no significant effects on the expression levels of BDNF and trk B [225].  
 Although this new method of testing may potentially allow medical 
examiners to determine and assign an accidental or suicide manner of death in 
undetermined overdose deaths by drug/ethanol overdose when medical and 
investigational evidence is inconclusive, as well as reestablish their professional 
authority, caution must be exercised in accepting the guidelines in its current 
state. The proposed state of enhanced serotonergic dysfunction, HPA axis 
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activity, and BDNF deficiency that is indicative of suicidal behavior was 
formulated from a limited number of studies. This may be due to the difficulty in 
procuring samples for study, but nonetheless the observations from a larger 
number of studies should be incorporated into the guideline. In addition, although 
the studies have also shown that effects such as age and postmortem interval 
did not significantly affect the expression of BDNF and trk B, the validity of the 
statement is also challenged by the limited pool of subjects from which the 
information was taken. BDNF has been known to decrease with age and the 
postmortem interval in the studies were limited to a maximum of 36 hours; 
therefore, areas of future research could include studying the effects of age from 
a larger population and the effects of postmortem interval from a longer period of 
time. In addition, this guideline did not take in consideration the effect that sex 
has on the expression of serotonergic dysfunction, HPA axis activity, and BDNF 
deficiency. The effect of gender has been shown to play a role in the BDNF 
signaling and expression of 5-HT1A receptors [237-239]. By incorporating the 
findings in these areas of study, this guideline may gain further support and 
develop into an accepted method of identifying a predisposition towards suicidal 
behavior.  
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